Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients

6/14/24 6:16:34 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $STTK alert in real time by email

The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached. Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached.

Get the next $STTK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STTK

Date	Price Target	Rating	Analyst
10/2/2024	$8.00 → $2.00	Buy → Neutral	Citigroup
10/2/2024		Buy → Hold	Needham
10/1/2024		Buy → Neutral	H.C. Wainwright
6/17/2024		Buy → Neutral	BTIG Research
8/31/2022	$12.00	Buy	BTIG Research
6/1/2022	$13.00	Buy	Citigroup
5/2/2022	$28.00	Buy	H.C. Wainwright

More analyst ratings

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today reported financial results for the quarter ended September 30, 2024 and provided recent business highlights. "Last mo
11/14/24 7:00:00 AM ET
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T
10/1/24 6:30:00 AM ET
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-one meetings at BTIG's Virtual Biotechnology Conference, taking place August 5-6, 2024. Presentation DetailsConference: BTIG Virtual Biotechnology ConferenceFormat: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Offi
7/30/24 5:00:00 PM ET
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care

$STTK
Leadership Updates

Live Leadership Updates

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre
3/4/24 7:00:00 AM ET
$IMNM
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To
11/6/23 9:28:40 AM ET
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Shattuck Labs Announces Changes to its Board of Directors
AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the
10/28/21 4:30:00 PM ET
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care

Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients

Chat with this insight

Recent Analyst Ratings for $STTK

$STTK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Shattuck Labs downgraded by Citigroup with a new price target

Shattuck Labs downgraded by Needham

Shattuck Labs downgraded by H.C. Wainwright

$STTK Press Releases

Fastest customizable press release news feed in the world

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

$STTK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

$STTK Leadership Updates

Live Leadership Updates

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

Shattuck Labs Announces Changes to its Board of Directors

$STTK SEC Filings

SEC Form 10-Q filed by Shattuck Labs Inc.

Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Shattuck Labs Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

$STTK Market Insights

Live Market Insights

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $16

Citigroup Maintains Buy on Shattuck Labs, Lowers Price Target to $9

$STTK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

Chief Executive Officer Schreiber Taylor bought $50,011 worth of shares (14,400 units at $3.47), increasing direct ownership by 72% to 34,502 units (SEC Form 4)

$STTK Financials

Live finance-specific insights

$STTK Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

Chief Executive Officer Schreiber Taylor bought $50,011 worth of shares (14,400 units at $3.47), increasing direct ownership by 72% to 34,502 units (SEC Form 4)

Recent Analyst Ratings for
$STTK

$STTK
Analyst Ratings

$STTK
Press Releases

$STTK
Large Ownership Changes

$STTK
Leadership Updates

$STTK
SEC Filings

$STTK
Market Insights

$STTK
Insider Trading

$STTK
Financials

$STTK
Insider Purchases